Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVIDâ„¢ Conditional Marketing Authorization to Full Marketing Authorization in the European Union
Pfizer
JANUARY 27, 2023
This opinion from the CHMP confirms that the benefits of PAXLOVID in helping to reduce severe COVID-19-related outcomes, including hospitalization and death, in high risk patients continue to outweigh its potential risks. PAXLOVID is currently approved or authorized for conditional or emergency use in more than 70 countries to treat COVID-19.
Let's personalize your content